BioForward Announces Winners of Fourth Annual Wisconsin Biohealth Awards
Dr. Allen W. Cowley, Jr., is a professor and chair of the department of Physiology at the Medical College of Wisconsin (MCW). Dr. Cowley is an international leader in cardiovascular research and has made seminal observations that have advanced understanding of hypertension. As the chair of Physiology, Dr. Cowley forged the development and integration of genomics, bioinformatics, computational biology and physiology to address questions of clinical importance. He spearheaded efforts which resulted in the investment of more than $100 million for the development of the needed infrastructure to link genes to complex physiological functions and diseases. Dr. Cowley has received many awards and honors recognizing his work, including MCW’s Distinguished Service Award, multiple honorary doctorates, and awards from the American Physiological Society and the American Heart Association.
Kevin Conroy is chairman and chief executive officer of Exact Sciences Corporation. Exact Sciences is focused on the early detection and prevention of cancer, establishing a new standard for colon cancer screening with its noninvasive, advanced DNA screening test, Cologuard. Before joining Exact Sciences, Mr. Conroy served as president and chief executive officer of Third Wave Technologies, a molecular diagnostics company, until the company’s acquisition by Hologic, Inc. Previously, he served as intellectual property counsel at GE Healthcare and in private practice.
“These awards are a testament to the dedication and innovation both Dr. Allen Cowley and Kevin Conroy have put forth in Wisconsin’s biohealth industry,” said Lisa Johnson, CEO of BioForward. “We’re honored to recognize two individuals who have made a significant impact on both global human health and Wisconsin’s economy.”
The Wisconsin Biohealth Awards were launched in 2015, recognizing scientific and business successes that have brought Wisconsin to be among the top leaders in integrated health solutions. Past awardees include Dr. Lynn-Allen Hoffman of Stratatech-Mallinckrodt, Cynthia LaConte of The Dohmen Company, Dr. James Thompson of UW-Madison, Ralph Kauten of Lucigen, Dr. Hector DeLuca of UW-Madison and Deltanoid Pharmaceuticals, and Bill Linton of Promega.
Dr. Allen W. Cowley, Jr. and Kevin Conroy will be honored during a lunch ceremony at the Wisconsin Biohealth Summit presented by BioForward on October 9, 2018, at the Overture Center in Madison, Wisconsin. Additional information on the Wisconsin Biohealth Awards, awardees, and the Wisconsin Biohealth Summit can be found at www.wisconsinbiohealthsummit.org.
BioForward serves as the independent voice of Wisconsin’s biohealth industry, providing services and resources to support the growth of our industry throughout the U.S. and the world. BioForward is the only Wisconsin organization representing over 200 biohealth member companies including biotech, biopharma, medical device, diagnostics, digital health, as well as research institutions, and service providers. Learn more about BioForward Wisconsin and their initiatives for 2018 at www.bioforward.org.
About Medical College of Wisconsin
With a history dating back to 1893, The Medical College of Wisconsin is dedicated to leadership and excellence in education, patient care, research and community engagement. More than 1,200 students are enrolled in MCW’s medical school and graduate school programs in Milwaukee, Green Bay, and Central Wisconsin. MCW’s School of Pharmacy opened in 2017. A major national research center, MCW is the largest research institution in the Milwaukee metro area and second largest in Wisconsin. In FY2016, faculty received more than $184 million in external support for research, teaching, training and related purposes. This total includes highly competitive research and training awards from the National Institutes of Health (NIH). Annually, MCW faculty direct or collaborate on more than 3,100 research studies, including clinical trials. Additionally, more than 1,500 physicians provide care in virtually every specialty of medicine for more than 525,000 patients annually.
About Exact Sciences
Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences or find Exact Sciences on Facebook.